Nivolumab/Ipilimumab Approaches EU Approval in Unresectable or Advanced HCC
The EMA’s CHMP has adopted a positive opinion regarding frontline nivolumab plus ipilimumab in unresectable or advanced hepatocellular carcinoma.
Related Articles
NCI study: Prevention and screening saved more lives than treatment in five common cancer types over the past half-century – The Cancer Letter
Over the last 45 years, prevention and screening interventions have made a greater contribution to averting cancer deaths than have improvements in treatment, according to…
Olaparib Increases OS in Patients with Germline/Somatic BRCA+ Relapsed Ovarian Cancer
Patients with relapsed ovarian cancer who had germline or somatic BRCA mutations saw greater OS with olaparib, according to data from the LIGHT trial.
Relying on Progress Against Multiple Myeloma Progression
Diagnosed with multiple myeloma in 2004, Vicki Jones has lived with her cancer for more than 20 years thanks to chemotherapy and immunotherapy.
Datopotamab Deruxtecan Wins CHMP Positive Opinion for Previously Treated HR+ Breast Cancer
Datopotamab deruxtecan approaches approval in Europe as an option for patients with previously treated hormone receptor–positive breast cancer.
Maximizing the dual benefit of pet dogs in cancer trials
Nature Reviews Cancer – Pet dogs with cancer facilitate comparative oncology, enhancing translational research. In this Comment, Lenz and Atherton highlight comparative oncology successes,…
Latest Updates in Navtemadlin Therapy for Patients With Myelofibrosis
Navtemadlin therapy demonstrated efficacy and safety for patients with JAK inhibitor relapsed/refractory myelofibrosis, as well as improved biomarkers of disease burden, according to data presented…
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
Key PointsBOVen was safe and effective for the frontline treatment of TP53-mutant MCL.The 2-year progression-free survival of 72% compares favorably with p
Membership – Society of Surgical Oncology
Join over 3,000 surgical oncologists worldwide. The Society of Surgical Oncology (SSO) is dedicated to improving multidisciplinary patient care by advancing the science, education, and…
Myelofibrosis Disease Biology: From Molecular Mechanisms to Clinical Phenotypes and Therapeutic Targets
Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations, ultimately informing the development of targeted therapeutic approaches for this…
EGFR-Mutant NSCLC Diagnosis: Insights from Patients and Clinicians
Panelists discuss Melinda’s experience with her lung cancer diagnosis, including her symptoms, diagnostic tests (such as imaging and blood work), and the progression of her…
